top of page
deliverysystem_vignette.jpg

Groundbreaking innovation

The SpyGlass Pharma™ Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.

Spyglass Platform Pipeline

Spyglass-Platform-Pipeline-20250321_edit
texture_bg.jpg

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic biotechnology company, today announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Technology

Tel: 949-284-6904

About

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

Investors

CONTACT US

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2025 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page